CX 2009

Drug Profile

CX 2009

Alternative Names: CD166 Probody Drug Conjugate; CX-2009

Latest Information Update: 16 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CytomX Therapeutics; ImmunoGen
  • Developer CytomX Therapeutics
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 01 Jun 2017 Phase-I/II clinical trials in Solid tumours (Metastatic disease, Late-stage disease, Inoperable/Unresectable, Second-line therapy or greater, Monotherapy) in USA (unspecified route) (NCT03149549)
  • 05 May 2017 CytomX Therapeutics files an IND application for Cancer
  • 05 May 2017 CytomX Therapeutics plans to initiate the phase I/II PROCLAIM-CX-2009 trial for Solid tumours (Monotherapy, Metastatic disease, Late-stage disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (NCT03149549)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top